Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Recommendation for validation and quality assurance of non-invasive prenatal testing for foetal blood groups and implications for IVD risk classification according to EU regulations

Research output: Contribution to journalReviewResearchpeer-review

DOI

  1. Validation of a standardized donor health questionnaire across substances of human origin

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Determinants of intention to return to donate blood among first-time blood donors in Ghana

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. How donor selection criteria can be evaluated with limited scientific evidence: lessons learned from the TRANSPOSE project

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Laboratory Monitoring of Mother, Fetus, and Newborn in Hemolytic Disease of Fetus and Newborn

    Research output: Contribution to journalReviewResearchpeer-review

  2. Prenatal prediction of fetal Rh C, c and E status by amplification of maternal cfDNA and deep sequencing

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Prediction of ABO hemolytic disease of the newborn using pre- and perinatal quantification of maternal anti-A/anti-B IgG titer

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Frederik Banch Clausen
  • Åsa Hellberg
  • Gregor Bein
  • Peter Bugert
  • Dieter Schwartz
  • Tadeja Dovc Drnovsek
  • Kirstin Finning
  • Katarzyna Guz
  • Katri Haimila
  • Christine Henny
  • Helen O'Brien
  • Agnieszka Orzinska
  • Kirsten Sørensen
  • Steinunn Thorlacius
  • Agneta Wikman
  • Gregory Andrew Denomme
  • Willy Albert Flegel
  • Christoph Gassner
  • Masja de Haas
  • Catherine Hyland
  • Yanli Ji
  • William J Lane
  • Núria Nogués
  • Martin L Olsson
  • Thierry Peyrard
  • C Ellen van der Schoot
  • Christof Weinstock
  • Tobias Legler
View graph of relations

BACKGROUND AND OBJECTIVES: Non-invasive assays for predicting foetal blood group status in pregnancy serve as valuable clinical tools in the management of pregnancies at risk of detrimental consequences due to blood group antigen incompatibility. To secure clinical applicability, assays for non-invasive prenatal testing of foetal blood groups need to follow strict rules for validation and quality assurance. Here, we present a multi-national position paper with specific recommendations for validation and quality assurance for such assays and discuss their risk classification according to EU regulations.

MATERIALS AND METHODS: We reviewed the literature covering validation for in-vitro diagnostic (IVD) assays in general and for non-invasive foetal RHD genotyping in particular. Recommendations were based on the result of discussions between co-authors.

RESULTS: In relation to Annex VIII of the In-Vitro-Diagnostic Medical Device Regulation 2017/746 of the European Parliament and the Council, assays for non-invasive prenatal testing of foetal blood groups are risk class D devices. In our opinion, screening for targeted anti-D prophylaxis for non-immunized RhD negative women should be placed under risk class C. To ensure high quality of non-invasive foetal blood group assays within and beyond the European Union, we present specific recommendations for validation and quality assurance in terms of analytical detection limit, range and linearity, precision, robustness, pre-analytics and use of controls in routine testing. With respect to immunized women, different requirements for validation and IVD risk classification are discussed.

CONCLUSION: These recommendations should be followed to ensure appropriate assay performance and applicability for clinical use of both commercial and in-house assays.

Original languageEnglish
JournalVox Sanguinis
Volume117
Issue number2
Pages (from-to)157-165
Number of pages9
ISSN0042-9007
DOIs
Publication statusPublished - Feb 2022

Bibliographical note

© 2021 International Society of Blood Transfusion.

    Research areas

  • blood group, cell-free DNA, EU, foetal RHD genotyping, HDFN, quality assurance, validation

ID: 73388468